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Endogenous Nociceptin ⁄ Orphanin FQ System Involvement in Hypothalamic-
Pituitary-Adrenal Axis Responses: Relevance to Models of Inﬂammation
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The peptide nociceptin⁄orphanin FQ (N⁄OFQ) is widely distributed
throughout the central nervous system (1–3) and immune systems,
consistent with its broad spectrum of actions. Its effects are medi-
ated via activation of the speciﬁc G-protein-coupled receptor, NOP
(1, 4–6). The N⁄OFQ-NOP system robustly modulates pain threshold,
learning and memory, locomotion, cardiovascular parameters (7–9)
and has signiﬁcant potential with respect to neuroendocrine and
neuroimmune integration. Various populations of immune cells,
including mouse lymphocytes (10), human peripheral blood
mononuclear cells (11) and circulating lymphocytes and monocytes
(12, 13), express the NOP receptor. Our laboratory has recently
demonstrated that a range of stimuli relevant to inﬂammation,
including mitogens, corticotrophin-releasing factor (CRF) and pro-
inﬂammatory cytokines, all increase endogenous N⁄OFQ secretion
by immune cells in culture and that N⁄OFQ itself may subserve
anti-inﬂammatory actions involving suppression of interleukin (IL)-2
(14) and tumour necrosis factor (TNF)-a secretion, with potential
interaction with prostanoids (15).
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Nociceptin⁄orphanin FQ (N⁄OFQ) peptide and its receptor (NOP) function in the neuromodulation of
anxiety, stress and hypothalamic-pituitary-adrenal (HPA) axis activity. We investigated the endoge-
nous NOP system using the selective NOP antagonist, UFP-101, during the HPA axis response to bac-
terial endotoxin, lipopolysaccharide (LPS). Although i.c.v. N⁄OFQ (1 lg⁄rat) had no signiﬁcant effect
on LPS-induced (250 lg⁄rat i.p) plasma corticosterone release at 30 or 60 min post-i.c.v. injection,
i.c.v. UFP-101 (1 lg⁄rat)⁄LPS signiﬁcantly attenuated plasma adrenocorticotrophic hormone and corti-
costerone at the 30-min time-point compared to i.c.v saline (0.9%)⁄LPS. Parvocellular paraventricular
nucleus (PVN) corticotrophin-releasing factor (CRF) and corticotrophic pro-opiomelanocortin (POMC),
but not parvocellular PVN arginine vasopressin (AVP), mRNA expression was signiﬁcantly increased by
LPS compared to non-LPS control. Intracerebroventricular UFP-101⁄LPS treatment was associated with
increased POMC mRNA expression 4 h after injection and a clear trend towards increased parvocellu-
lar CRF mRNA. Furthermore, i.c.v. UFP-101 was selectively associated with an LPS-induced increase in
parvocellular AVP mRNA, an effect that was absent in the i.c.v saline⁄LPS group. To determine
whether LPS challenge was associated with compensatory changes in N⁄OFQ precursor or NOP recep-
tor mRNAs, in a separate study, we undertook reverse transcriptase-polymerase chain reaction analy-
sis of preproN⁄OFQ and NOP transcripts. In support of an endogenous role for central N⁄OFQ in
inﬂammatory stress, we found that LPS signiﬁcantly increased preproN⁄OFQ transcript expression in
the hypothalamus 4 h after injection compared to the saline control. No changes in preproN⁄OFQ
mRNA level in the hippocampus or basal forebrain (including bed nucleus of stria terminalis) were
seen, albeit at 4 h. LPS was associated with a signiﬁcant attenuation of NOP mRNA in the basal fore-
brain at 4 h, possibly as a compensatory response to increased N⁄OFQ release. Although the exact
mechanisms require elucidation, the ﬁndings obtained in the present study provide evidence indicat-
ing that the endogenous NOP system is involved in the acute HPA axis response to immune chal-
lenge.
Key words: nociceptin, nociceptin⁄orphanin FQ peptide receptor, hypothalamic pituitary adrenal
axis, lipopolysaccharide, mRNA.
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From Molecular to Translational NeurobiologyIn models of inﬂammation, exogenous N⁄OFQ application
exerts multifunctional effects in neurones and glia, causing inhi-
bition of lipopolysaccharide (LPS)-induced IL-1b, IL-6 and TNF-a
release from cultured astrocytes (16), LPS-induced IL-1b mRNA
expression in cerebral cortical microglia (17), attenuation of sur-
gical-stress-induced macrophage IL-1b transcript expression (18)
and down-regulation of spinal dorsal horn IL-1b, IL-6 and TNFa
mRNA expression in adjuvant-induced arthritis (16). These ﬁnd-
ings are consistent with protective anti-inﬂammatory effects of
N⁄OFQ over local and systemic immune responses including ne-
uroinﬂammation. Furthermore, expression of N⁄OFQ-like immuno-
reactivity increases in embryonic and adult mouse dorsal root
ganglion neurones after LPS treatment in vitro (19), LPS and
pro-inﬂammatory cytokines increase N⁄OFQ precursor mRNA in
astrocytes (20, 21) and the superantigen, staphylococcal entero-
toxin A (SEA), increases expression of N⁄OFQ precursor mRNA levels
in amygdala and hypothalamic extracts of mouse brain (22). These
ﬁndings identify the counter-regulatory role of N⁄OFQ-NOP with
regard to neuroimmune responses. Interestingly, N⁄OFQ precursor
knockout mice show attenuated lymphoid organ expression of cyto-
kine transcripts (TNFa and IL-1b) after challenge with SEA, and
N⁄OFQ peptide given systemically to normal mice stimulates levels
of circulating TNFa in response to SEA (23), which is consistent
with in vivo immunomodulatory actions. Thus, the theoretical
potential of the N⁄OFQ-NOP system with regard to inﬂammatory
disorders or conditions associated with neuroimmune activation,
including neurodegenerative or neuropsychiatric diseases, necessi-
tates further evaluation, especially in consideration of the fact that
N⁄OFQ precursor knockout mice display elevated basal and post-
stress corticosterone levels compared to wild-type mice (24), which
complicates the assessment of immunological responsiveness
in vivo.
It is important to consider the central mechanism of action of
NOP receptors in the control of neuroinﬂammation. Although
recent research indicates a role for N⁄OFQ-NOP in the peripheral
immune system, little is known regarding the central role of
N⁄OFQ-NOP in inﬂammation models in vivo. In particular, we
sought to investigate the interaction between N⁄OFQ-NOP and
hypothalamic-pituitary-adrenal (HPA) axis activity, which is known
to be critical to the inﬂammatory response, on the basis of recent
evidence supporting a neuroendocrine role for N⁄OFQ-NOP. Stress
studies have concentrated on the role of N⁄OFQ-NOP in models rel-
evant for psychological stress (25, 26). For example, central injec-
tion of N⁄OFQ peptide augments the corticosterone response to
novel environment stress in rats but has no effect on restraint
stress-induced corticosterone levels (27). We have demonstrated
that central injection of the peptidic NOP antagonist, UFP-101,
([Nphe
1,Arg
14,Lys
15]N⁄OFQ-NH2), is able to fully attenuate the
effects of i.c.v. N⁄OFQ on HPA axis activity (28) and prolong
restraint stress-induced corticosterone release (29). This suggests
that endogenous N⁄OFQ neurotransmission, and concomitant acti-
vation of the NOP receptor, are important for restraining the HPA
axis response to the physical⁄psychological stress of restraint.
Because different types of stressor activate the HPA axis, potentially
invoking hierarchical pathways, the effect of N⁄OFQ-NOP system
involvement in the HPA axis response to other models of stress
[e.g. physical⁄immunological challenge using bacterial endotoxin
(LPS)] is required to establish the functional activation of central
N⁄OFQergic pathways and to clarify the role of N⁄OFQ-NOP in the
ﬁne-tuning of the acute stress response.
We have previously shown that i.c.v. UFP-101 is able to prolong
the acute HPA axis response to a 60-min restraint stress (29),
implicating endogenous N⁄OFQ release in the termination of the
neuroendocrine stress response. In the present study, the principal
aim was to determine the effects of UFP-101 on the HPA response
to LPS challenge (i.e. an immunological stressor). In addition, we
also characterised the effect of i.c.v. N⁄OFQ on the corticosterone
response to LPS challenge and the effect of systemic LPS on
prepro-nociceptin (preproN⁄OFQ) and NOP mRNA levels in the rat
forebrain.
Materials and methods
Animals
Adult male Sprague-Dawley rats weighing 200–220 g (Harlan, Bicester, UK)
were housed in a temperature and humidity controlled environment under a
12 : 12 h light⁄dark cycle (lights on 07.00h). Food and water were available
ad lib and all experiments were carried out in strict accordance with UK.
Home Ofﬁce regulations [Animals (Scientiﬁc Procedures) Act 1986].
Surgery
Three days prior to experiment rats were implanted with an intravenous
(i.v.) cannula placed in the right external jugular vein under Saffan anaes-
thesia (1.4 ml⁄kg; Schering-Plough, Welwyn Garden City, UK). Anaesthesia
was maintained via the i.v. cannula with a stainless steel tubing i.c.v. guide
cannula (22-gauge) terminating 1 mm above the left lateral ventricle
[0.8 mm caudal and 1.5 mm lateral to Bregma; coordinates derived from the
atlas of Paxinos and Watson (30)] implanted and fastened to the skull with
micro-screws and dental cement. A dummy cannula was inserted into the
guide cannula to prevent any blockage during the recovery period and was
removed the evening prior to the experiment so that animals would remain
unstressed on the morning of the experiment. Guide and dummy cannulae
were obtained from Plastics One (Roanoke, VA, USA). After surgery, rats
were individually housed. During the post-operative period, the i.v. cannulae
were ﬂushed daily with heparin (25 IU⁄ml) via a sampling line to maintain
patency and habituate the rats to the experimental procedure.
Experiment 1: Effect of nociceptin i.c.v. on the
corticosterone response to LPS
All experiments began between 09.30–10.00 h. Animals were randomly
assigned into four treatment groups and received i.c.v. injections (5 ll total
volume in 1 min) of either vehicle [0.9% sterile saline (Sal)] or N⁄OFQ
(1.0 lg⁄rat in 0.9% sterile saline; Tocris, Bristol, UK). Immediately after i.c.v.
injection, rats received i.p. injections of either lipopolysaccharide
(250 lg⁄0.5 ml 0.9% sterile saline; Sigma, Poole, UK, LPS serotype 055:B5)
or 0.9% sterile saline control (0.5 ml). Treatment groups comprised Sal⁄Sal
control, Sal⁄LPS, NOFQ⁄Sal or NOFQ⁄LPS. Blood samples (250 ll) for the
determination of basal plasma corticosterone concentrations were taken
prior to the administration of i.c.v. and i.p. injections. Further blood samples
were taken at 30 and 60 min post-i.c.v. injection. All blood sampling was
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rinised saline-(25 IU⁄ml) ﬁlled sampling line connected to the previously
implanted i.v. cannula. After each blood sample was taken, the volume of
blood removed was replaced with an equal volume of heparinised saline.
Plasma was obtained from blood samples by centrifugation and the samples
stored at )20  C until assayed.
Experiment 2: Effect of the NOP antagonist, UFP-101, i.c.v.
on the HPA axis response to LPS
In this study, animals were randomly assigned to four treatment groups.
Two of the groups received i.p. injections of 0.9% sterile saline (0.5 ml total
volume) immediately after an i.c.v injection of 0.9% sterile saline control
(5 ll total volume injected over 1 min) or UFP-101 (1 lg⁄rat in 5 ll sterile
0.9% saline vehicle injected over 1 min). These represented the non-LPS
groups. The remaining two groups of rats received i.p. injections of LPS
(250 lg in 0.5 ml sterile 0.9% saline; as above) immediately after i.c.v. injec-
tion of sterile 0.9% saline (5 ll total volume) or UFP-101 (1 lg⁄rat in 5 ll
sterile 0.9% saline). Treatment groups comprised Sal⁄Sal control, UFP⁄Sal,
Sal⁄LPS or UFP⁄LPS.
Blood samples (250 ll) for the determination of basal plasma hormone
concentrations were taken prior to the administration of i.c.v. and i.p. injec-
tions. Further blood samples were taken at 30 and 60 min post-i.c.v. injec-
tion. All blood sampling was carried out with the animal freely moving
about the home cage via a heparinised saline-ﬁlled (25 IU⁄ml) sampling line
connected to the previously implanted i.v. cannula. After each blood sample
was taken, the volume of blood removed was replaced with an equal vol-
ume of heparinised saline. Plasma was obtained from blood samples by
centrifugation and the samples stored at )20  C until assayed. At 4 h
post-i.c.v. injection, animals were killed by decapitation and the brains and
pituitaries dissected out, frozen on dry ice and stored at )80  C. Sections
(12 lm thick) of pituitary and brain (including the hypothalamic
paraventricular nucleus, PVN) were prepared using a cryostat (Bright
Instruments, Huntingdon, UK) and stored at )80  C until required for in situ
hybridisation.
Determination of plasma hormone concentrations
Plasma adrenocorticotrophic hormone (ACTH) concentrations were determined
using a commercially available enzyme-linked immunosorbent assay (ELISA)
kit (Biomerica, California, CA, USA). Plasma samples were diluted 1 : 5 in
Biomerica CAL A zero calibrator buffer (bovine serum albumin⁄equine serum
solution). The reported detection limit was 0.46 pg⁄ml with a calculated intra-
assay variation of < 5% and an inter-assay variation of < 12%. Plasma corti-
costerone concentrations were determined as described previously (Harbuz
et al. 1992) using antiserum supplied by Dr G. Makara (Institute of Experimen-
tal Medicine, Budapest, Hungary). The tracer used was [
125I]-corticosterone
(MP Biomedicals, Cambridge, UK) with a speciﬁc activity of 2–3 mCi⁄mg. The
intra-assay coefﬁcient of variation was < 12%.
In situ hybridisation histochemistry
In situ hybridisation histochemistry was performed as described previously
by Harbuz and Lightman (31). Oligonucleotide probes complementary to part
of the exonic sequences of arginine vasopressin (AVP), CRF or pro-opiomela-
nocortin (POMC) mRNA and previously characterised (31, 32) were used.
Probes were labelled with [
35S]-labelled dATP (1250 Ci⁄mmol; Perkin Elmer,
Boston, MA, USA) using terminal deoxyribonucleotidyl transferase (Roche,
Burgess Hill, Sussex, UK) and column puriﬁed with Nuctrap Puriﬁcation
Columns (Stratagene, La Jolla, CA, USA). Approximately 100 000 c.p.m. of
probe per 45 ll of hybridisation buffer was applied to each slide. Hybridisa-
tion was performed overnight at 37  C. All the sections for each experiment
were processed at the same time. Sections were then washed at 55  C and
room temperature in sodium citrate buffer and rinsed in distilled water
before being air dried. Dried sections, together with a [
14C]-labelled standard
(American Radiolabeled Chemicals Inc., St Louis, MO, USA) were opposed to
Hyperﬁlm autoradiography ﬁlm (Amersham Biosciences, Little Chalfont, UK).
AVP- and POMC-labelled sections were exposed for 3 days and CRF-labelled
sections were exposed for 14 days. After ﬁlm development, densitometric
analysis of the autoradiographic images was carried out using a computer-
assisted image analysis system (NIH IMAGE, version 1.62; NIH, Bethesda, MD,
USA). Optical density values were referenced against the linear portion of
the calibration curve produced using the [
14C] standards. Analysis of parvo-
cellular AVP mRNA level involved ﬁltering out the signal from the magno-
cellular component of the PVN using the thresholding tool available in NIH
image. Because magnocellular neurones contain a large excess of AVP
mRNA compared to the parvocellular cells and therefore bind more probe,
the darker signal can be readily identiﬁed on the ﬁlm and omitted from the
analysis. Data are presented as the mean  SEM percentage change from
control (assigned an arbitrary value of 100%) . Although we are conﬁdent
of the robustness of this technique and its ability to identify subtle changes
in parvocellular AVP mRNA (33), this method of analysis may increase the
possibility of false negative results.
Experiment 3: Effect of LPS treatment on preproN⁄OFQ
and NOP receptor mRNA level in rat forebrain
Brain dissection
Animals were administered LPS i.p. (250 lg⁄rat) or sterile saline (0.9%) con-
trol (in a volume of 0.5 ml⁄rat) 4 h prior to killing and removal of the brain.
This time-point was selected on the basis of previous studies showing SEA-
induced changes in preproN⁄OFQ expression in the brain (22). Brains were
subsequently dissected according to the method of Glowinski and Iversen
(34), as described previously (35), carried out under sterile conditions on
pre-chilled Petri dishes. The cerebellum and pons were separated from the
rest of the brain and a transverse section made at the level of the optic
chiasm that deﬁnes the anterior part of the hypothalamus and passes
through the anterior commissure. The hypothalamus, basal forebrain
[comprising the caudate nucleus, nucleus accumbens, globus pallidus, ven-
tral pallidum and bed nucleus of stria terminalis (BNST)] and hippocampus
regions were excised and subject to the RNA extraction procedure.
Isolation of RNA from rat brain
RNA was isolated from rat brain tissue (75-mg samples) by guanidinium
thiocyanate–phenol–chloroform extraction according to the method of
Chomczynski and Sacchi (36). After dissection, brain samples were immedi-
ately placed into 750 ll of lysis buffer (4 M guanidinium thiocyanate (dena-
turing solution), 25 mM sodium citrate, 0.5% sarcosyl, 0.1 M
b-mercaptoethanol). Lysed cell products were transferred to a sterile micro-
centrifuge tube to which 75 ll of sodium acetate (2 M, pH 4.0), 750 llo f
water-saturated phenol and 150 ll of chloroform : isoamyl alcohol (49 : 1)
were added. Samples were then shaken for 10 s to form an emulsion and
then cooled on ice for 15 min followed by centrifugation at 4  C for 20 min
at 10 000 g. The aqueous upper phase was transferred to a clean microcen-
trifuge tube and mixed with an equal volume of isopropanol at )20  C for
at least 1 h to enable RNA precipitation. After centrifugation at 4  C for
20 min at 10 000 g, the supernatant was discarded and the RNA pellet
resuspended in guanidinium thiocyanate denaturing solution. RNA was rep-
recipitated by addition of an equal volume of isopropranol at –20  C for a
further 1 h. After centrifugation at 4  C for 10 min at 10 000 g, the RNA
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gation at 4  C for 10 min at 7500 g. The supernatant was discarded and
the RNA pellet air-dried and resuspended in RNAse-free H2O. RNA concen-
tration was determined by ultraviolet spectrophotometry using GeneQuant
Pro (Amersham Biosciences) and purity was determined by calculation of
the A260 ⁄ 280 nm ratios. Total RNA samples (in 20 ll pure H2O) were then
stored at )80  C prior to reverse transcriptase-polymerase chain reaction
(RT-PCR).
RT-PCR for preproN⁄OFQ and NOP mRNAs
Levels of mRNA for preproN⁄OFQ, NOP receptor and GAPDH (i.e. house-
keeping gene) were determined by semi-quantitative RT-PCR using the
Expand Reverse Transcriptase kit (Roche). One microgram of total RNA and
1 ll Oligo(dT)15 (Roche) underwent initial denaturation for 10 min at 65  C
in a volume of 10.5 ll of RNAse-free H2O and were then immediately
cooled on ice. Reverse transcription was then performed at 42  C for 1 h by
addition of 1· Expand Reverse Transcriptase Buffer, 10 mM dithiothreitol,
1m M each deoxynucleotide triphosphate (dNTP), 20 U of ribonuclease inhib-
itor (RNAsin; Promega, Southampton, UK), and 50 U of Expand Reverse
Transcriptase in a total volume of 20 ll. The reaction was terminated by
placing sample tubes on ice. Primers for ampliﬁcation of the cDNA for
preproN⁄OFQ were: sense, 5¢-CCCACGGCTGCACCATGAAAATC-3¢; antisense,
5¢-TTCCTCTCACCTGGCCCTACGAGA-3¢ (37) with a predicted PCR ampliﬁcation
product of 840 bp. Primers for the cDNA for NOP receptor were: sense, 5¢-A
TGGAGTCCCTCTTTCCTGCT-3¢; antisense, 5¢-ACATGTTGTAGTAGTCGATAGCA-3¢
with a predicted PCR ampliﬁcation product of 399 bp. Primers for the cDNA
for GAPDH were: sense, 5¢-GAACGGGAAGCTCACTGGCAT-3¢; antisense,
5¢-GTCCACCACCCTGTTGCTGTTAG-3¢ with a predicted PCR ampliﬁcation prod-
uct of 308 bp. NOP and GAPDH primer pairs were designed and validated
in-house. cDNA aliquots (2 ll) were ampliﬁed by PCR in a 25-ll reaction
volume by Taq DNA polymerase (0.6 U; Abgene, Epsom, UK) in reaction buf-
fer [75 mM Tris–HCl pH 8.8, 20 mM (NH4)2SO4, 0.1% Tween 20] including
2m M MgCl2, dNTPs (0.2 mM each) and 50 pmol of forward and reverse oli-
gonucleotide primers. Ampliﬁcation reactions were performed using a ther-
mal cycler (Perkin-Elmer) and terminated prior to the end of the exponential
phase (preproN⁄OFQ, 26 cycles; NOP receptor, 26 cycles; GAPDH, 20 cycles).
Optimised ampliﬁcation conditions for PCR involved denaturation at 95  C
for 2 min, followed by the appropriate number of cycles at 95  C for 20 s,
annealing at 55  C for 45 s, extension at 72  C for 1 min and completion
by a ﬁnal extension at 72  C for 10 min. Ampliﬁed PCR products (15 ll)
were mixed with 5 ll of loading buffer (0.5% sodium dodecyl sulphate,
25 mM ethylenediaminetetraacetic acid, 25% Ficoll, 0.15% bromophenol
blue) and resolved on a 2% agarose gel containing 0.1 lg⁄ml ethidium bro-
mide by electrophoresis. Semi-quantitative analysis of resolved products was
achieved by visualisation and scanning densitometric measurement of band
intensity using Bio-Rad Quantity One analysis software and the Gel Doc
2000 Gel Documentation System (Bio-Rad, Hercules, CA, USA). The relative
band intensity (pixel intensity per band) of the PCR product (preproN⁄OFQ
or NOP receptor) was expressed as a ratio against data for the house-
keeping gene, GAPDH, determined in the same sample.
Statistical analysis
Radioimmunoassay and ELISA data were analysed using two-way ANOVA
followed by the post-hoc Fisher protected least-signiﬁcant difference test.
Data from the in situ hybridisation experiments were analysed using
one-way ANOVA and Bonferroni post-hoc tests. For RT-PCR studies, Mann–
Whitney U-tests were used to compare ratios of the mRNA of interest to
GAPDH between groups. In all tests, P < 0.05 was considered statistically
signiﬁcant.
Results
Experiment 1: Effect of the N⁄OFQ peptide i.c.v. on the
corticosterone response to LPS
Two-way ANOVA indicated a signiﬁcant effect of time (F3,56 = 58.4,
P < 0.001) and treatment (F3,56 = 14.7, P < 0.001) on plasma corti-
costerone concentration (Fig. 1). LPS injection signiﬁcantly increased
plasma corticosterone release at 30 and 60 min post-injection in
both i.c.v. injection groups, although N⁄OFQ peptide did not signiﬁ-
cantly modulate the LPS response. Saline injection i.p. to control
rats was without signiﬁcant effect on plasma corticosterone release
at the 30- and 60-min time-point. There was also no signiﬁcant
effect of either saline or N⁄OFQ peptide i.c.v on plasma corticoste-
rone in i.p. saline-injected rats.
Experiment 2: Effect of the NOP antagonist, UFP-101, i.c.v.
on the HPA axis response to LPS
Plasma hormone levels
Two-way ANOVA indicated a signiﬁcant effect of time (F3,48 = 19.87,
P < 0.001) and treatment (F3,48 = 24.72, P < 0.001) on plasma
ACTH concentration (Fig. 2A). There were no signiﬁcant differences
in basal levels of plasma ACTH at the 0 time point. There were no
signiﬁcant differences between the i.p. saline-treated control groups
(Sal⁄Sal and UFP⁄Sal) at any time point throughout the experiment.
Although LPS treatment caused a signiﬁcant increase in plasma
ACTH release, there was a signiﬁcant difference between Sal⁄LPS
and UFP⁄LPS groups at the 30-min time-point. Sal⁄LPS signiﬁcantly
increased plasma ACTH compared to the respective Sal⁄Sal control
group at 30 min post-i.c.v. injection (Sal⁄Sal: 24.9  6.63 pg⁄ml,
n = 9; Sal⁄LPS: 833.0  257.2 pg⁄ml, n = 5, P < 0.001). UFP⁄Sal
treatment had no signiﬁcant effect on ACTH secretion at 30 min
post-injection (UFP⁄Sal: 111.6 26.9 pg⁄ml, n = 6); however, UFP-
101 signiﬁcantly attenuated the effect of LPS on plasma ACTH level
at 30 min (UFP⁄LPS: 297.8  125.7 pg⁄ml, n = 8, P < 0.01). At
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Fig. 1. Plasma corticosterone concentration after treatment with i.c.v. saline
or 1 lg⁄rat of nociceptin⁄orphanin FQ (N⁄OFQ) peptide immediately prior
to i.p. injection of saline (Sal) or lipopolysaccharide (LPS, 250 lg⁄rat). Data
are presented as the mean  SEM plasma corticosterone concentration
(ng⁄ml) , n = 7; ***P < 0.001 versus saline-treated groups.
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was elevated to an equivalent extent between i.c.v saline and i.c.v.
UFP-101 groups (Sal⁄LPS: 888.5  116.4 pg⁄ml, n = 5; UFP⁄LPS:
798.0  160.7 pg⁄ml, n = 8, P < 0.001) compared to their respec-
tive i.p. saline groups (Sal⁄Sal: 26.2  15.96 pg⁄ml, n = 9; UFP⁄Sal:
101.9  54.83, n = 6).
Two-way ANOVA also indicated a signiﬁcant effect of time
(F3,50 = 54.15, P < 0.001) and treatment (F3,50 = 17.34, P < 0.001)
on plasma corticosterone secretion (Fig. 2B). There was no signiﬁ-
cant difference in the basal levels of corticosterone at time point 0.
Post-hoc tests indicated a signiﬁcant difference at the 30-min time
point between the two groups that received saline i.p. injections
(Sal⁄Sal and UFP⁄Sal), indicating that, under the UFP⁄Sal condition,
plasma corticosterone was increased compared to the Sal⁄Sal
control (P < 0.05). Consistent with the ACTH results i.p. LPS
treatment signiﬁcantly increased plasma corticosterone concentra-
tion at 30 min in the Sal⁄LPS group compared to the i.p. saline
control (Sal⁄Sal: 205.3  40.08 ng⁄ml, n = 9; Sal⁄LPS: 795.6 
117.6 ng⁄ml, n = 5, P < 0.001). Furthermore, i.c.v. UFP-101 signiﬁ-
cantly attenuated the LPS-induced CORT increase at the 30-min
time-point (P < 0.05), such that there was no difference between
UFP⁄Sal and UFP⁄LPS groups at this time (UFP⁄Sal: 461.9 
90.35 ng⁄ml, n = 7; UFP⁄LPS: 439.7  88.19 ng⁄ml, n = 8).
However, at 60 min post-i.c.v injection, plasma corticosterone levels
were signiﬁcantly elevated to an equivalent level in both LPS-trea-
ted groups compared to the i.p. saline control groups (Sal⁄LPS:
759.2  35.22 ng⁄ml, n = 5; UFP⁄LPS: 741.5  113.8 pg⁄ml,
n = 8, P < 0.001).
mRNA expression in the PVN and pituitary
One-way ANOVA indicated a signiﬁcant difference in AVP mRNA
expression between treatment groups (F3,29) = 3.020, P = 0.048;
Fig. 3A). Post-hoc tests revealed a signiﬁcant increase in AVP mRNA
expression in the UFP⁄LPS group only compared to the control
group (Sal⁄Sal: 100.0  12.01%, n = 8; UFP⁄Sal: 106.7  10.12%,
not signiﬁcant, n = 8; Sal⁄LPS: 104.7  11.55%, not signiﬁcant,
n = 6; UFP⁄LPS: 142.0  11.48%, P < 0.05, n = 8). Also in the
hypothalamic PVN, one-way ANOVA showed a signiﬁcant difference
in CRF expression between the treatment groups (F3,30 = 3.714,
P = 0.023; Fig. 3B). Post-hoc tests revealed a signiﬁcant increase in
CRF expression induced by only the Sal⁄LPS group because the
trend towards an increase seen with the UFP⁄LPS group just failed
to reach signiﬁcance (Sal⁄Sal: 100.0  19.84%, n = 9; Sal⁄Sal:
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P < 0.05, n = 7; UFP⁄LPS: 167.7  24.20%, not signiﬁcant, n = 8).
In the pituitary, POMC mRNA expression was signiﬁcantly affected
by treatment (F3,32 = 4.605, P = 0.009; Fig. 4). POMC mRNA was
signiﬁcantly increased by both of the LPS groups only, post-hoc
tests revealed no other signiﬁcant differences between the groups
(Sal⁄Sal: 100.0  2.728%, n = 10; UFP⁄Sal: 105.5  3.165%, not
signiﬁcant, n = 8; Sal⁄LPS: 114.1  4.660%, P < 0.05, n = 7;
UFP⁄LPS: 116.8  4.516%, P < 0.05, n = 8).
Experiment 3: Effect of LPS treatment on preproN⁄OFQ and
NOP receptor mRNA expression in rat forebrain
Levels of preproN⁄OFQ mRNA were examined by RT-PCR in hypo-
thalamus, basal forebrain and hippocampus from rat brain. A repre-
sentative digitised image showing ethidium bromide staining of
cDNAs for preproN⁄OFQ in rat hypothalamus from saline control
and LPS-treated rats is shown in Fig. 5. Band intensities provide an
index of levels of the corresponding mRNAs in the rat hypothala-
mus. Statistical analysis revealed that LPS treatment signiﬁcantly
increased preproN⁄OFQ mRNA in the hypothalamus compared to
saline-treated rats. There was a signiﬁcant difference between the
preproN⁄OFQ : GAPDH ratio in the hypothalamus in the LPS group,
representing a 49.64% increase in preproN⁄OFQ mRNA (mean pre-
proN⁄OFQ : GAPDH ratio = 2.08) relative to the control group (pre-
proN⁄OFQ : GAPDH ratio = 1.39, n = 6 per group, Mann–Whitney
U = 3.00, P < 0.01; Fig. 5A). LPS treatment, however, had no signiﬁ-
cant effect on preproN⁄OFQ mRNA levels in the basal forebrain or
hippocampus 4 h post-injection (Fig. 5B, C).
Levels of NOP mRNA were detected by RT-PCR in hypothalamus,
basal forebrain and hippocampus of LPS and saline-treated rats.
A representative digitised image showing ethidium bromide staining
of cDNAs for NOP mRNA in rat basal forebrain from saline control
and LPS-treated rats is shown in Fig. 6. Statistical analysis revealed
that there was a signiﬁcant difference in the NOP : GAPDH ratio in
the basal forebrain in LPS-injected rats (Control, mean ratio = 0.92;
LPS, mean ratio = 0.55), P < 0.05; n = 6 per group; Fig. 6B), repre-
senting a 40.2% decrease in NOP mRNA in this region in the LPS
group. LPS (250 lg⁄rat), however, had no signiﬁcant effect on NOP
mRNA level in hypothalamus or hippocampus 4 h post-injection
(Fig. 6A, C).
Discussion
In the present study, we have shown for the ﬁrst time that the
HPA axis activation response to bacterial endotoxin, LPS, challenge
can be signiﬁcantly attenuated by central blockade of NOP recep-
tors using the NOP receptor antagonist UFP-101. The robust reduc-
tion in both plasma ACTH and corticosterone in response to LPS
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neuroimmune role of the N⁄OFQ-NOP system in vivo. The signiﬁ-
cant attenuation of LPS-induced ACTH and corticosterone release
30 min after i.c.v. infusion of UFP-101 indicates that the acute
release of pituitary ACTH in response to LPS challenge is mediated
via a pathway involving endogenous N⁄OFQ release and activation
of NOP receptors. These results notably contrast with our recent
ﬁndings showing that UFP-101 prolongs the corticosterone
response to the stress of restraint (60 min), implicating endogenous
N⁄OFQ function in the termination of the stress response (29). In
the present study, the ﬁnding that UFP-101 attenuates the HPA
axis hormone response to acute LPS injection suggests that central
endogenous N⁄OFQ release is enhanced in response to inﬂamma-
tory stimulation. However, enhanced release of N⁄OFQ and associ-
ated activation of the HPA axis resulting in enhanced production of
adrenal glucocorticoids would effectively damp down the poten-
tially damaging inﬂammatory response, exerting a N⁄OFQ protective
effect in vivo. Interestingly, despite the clear attenuation of ACTH
and corticosterone responses to LPS in the i.c.v. UFP-101-treated
rats, when given alone, N⁄OFQ peptide i.c.v. did not extend the HPA
axis activation. The dose of N⁄OFQ injected (1 lg⁄rat in 5 ll i.c.v.)
is the same dose that we have previously demonstrated to activate
the HPA axis under basal conditions (28), possibly implying a ceiling
effect of the peptide in the LPS condition employed here. However,
in the present study, we did not observe an increase in basal corti-
costerone secretion in response to i.c.v. N⁄OFQ, as previously shown
(28). It is entirely possible that the i.p. saline injection procedure
and associated handling inﬂuenced the response to i.c.v. N⁄OFQ in
the present study. Furthermore, full dose–response studies would
be necessary to investigate the ability of exogenous N⁄OFQ peptide
application to modulate the HPA axis response to LPS challenge
in vivo. The saline i.p. injection may also, in part, explain the
observation that i.c.v. UFP-101⁄saline i.p. treatment caused a short-
lasting increase in corticosterone release, when, previously, we
found no effect of i.c.v. UFP-101 infusion on basal HPA axis activity
(28). Such ﬁndings indicate the potential of mildly stressful proce-
dures to inﬂuence the endogenous N⁄OFQ tone in vivo.
Because the effect of UFP-101 in the present study was only
observed in the ﬁrst 30 min post-LPS injection, it is possible that it
disrupts the mechanism or mechanisms responsible for the immedi-
ate, acute release of ACTH. By 60 min post-LPS administration,
plasma ACTH and corticosterone levels in UFP-101-treated LPS rats
were comparable with those of the LPS control rats and, by 4 h post-
injection, CRF and POMC mRNA transcripts for both LPS-treated
groups were elevated in response to activation of the HPA axis. The
elevation of plasma ACTH and corticosterone at 60 min correlates
with the reported time for peak peripheral LPS-induced plasma cyto-
kine levels that contribute to the extended glucocorticoid response to
immunological challenge (38–40). In response to LPS challenge, par-
vocellular PVN AVP mRNA expression was signiﬁcantly elevated in
the UFP-101-treated LPS rats versus the control 4 h after injection.
Although LPS alone has been reported to elevate AVP mRNA expres-
sion and stimulate AVP release (39–41), this is not a consistent effect
(42) and was also not observed in the present study. Centrally-
injected N⁄OFQ has been reported to inhibit dehydration-induced
AVP release and an inhibitory endogenous N⁄OFQ tone is involved in
the regulation of plasma AVP concentration (43). It is therefore pos-
sible that the combination of LPS challenge and removal of endoge-
nous N⁄OFQ tone by UFP-101 was able to stimulate up-regulation of
parvocellular PVN AVP mRNA expression, presumably in response to
enhanced AVP release at the median eminence.
In agreement with our in vivo ﬁndings showing UFP-101 medi-
ated attenuation of the HPA axis hormone response to LPS, our
RT-PCR studies conﬁrmed that LPS is a potent regulator of N⁄OF-
Qergic and NOP-responsive neurones in the brain. In addition to
our recent in vitro research demonstrating LPS induction of
immune-derived N⁄OFQ secretion, we have shown that the acute
LPS model affects N⁄OFQ–NOP in terms of mRNA expression in the
brain, consistent with a major role for this peptide in inﬂammation.
Previous research has demonstrated that in vivo challenge models,
such as carrageenan-induced paw inﬂammation, are associated
with increased preproN⁄OFQ mRNA in dorsal root ganglia (DRG)
(44, 45) and that LPS in vitro can also induce preproN⁄OFQ mRNA
in DRG neurones (19). Consistent with the effects of UFP-101 i.c.v.,
supporting tonic regulation of HPA axis responses in vivo, our
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proN⁄OFQ mRNA transcription is markedly increased in the hypo-
thalamus. It is particularly interesting to note that, although a
marked increase in synthesis of preproN⁄OFQ mRNA was seen in
the hypothalamus post-LPS stress, no change in expression of NOP
mRNA was detected in this region at the 4-h time-point. By con-
trast, NOP mRNA synthesis was signiﬁcantly reduced in the basal
forebrain region 4 h after LPS, without a change in preproN⁄OFQ
mRNA transcription. Although it is difﬁcult to interpret these ﬁnd-
ings in the context of local changes in gene expression after stress,
it may be suggestive of dissociation between preproN⁄OFQ and
NOP gene regulation, at least in terms of the response to LPS seen
at this time-point. Interestingly, hippocampal preproN⁄OFQ and
NOP mRNA transcript levels were not signiﬁcantly affected by LPS,
consistent with ﬁndings describing effects of SEA challenge on hip-
pocampal expression of preproN⁄OFQ mRNA 1–4 h post-injection
(22). SEA injection in mice was also reported to stimulate hypotha-
lamic preproN⁄OFQ mRNA expression 2 and 4 h post-injection (22),
which also concurs with our observations in rats.
Given our previous work implicating N⁄OFQ in the regulation of
basal and stress-induced changes in HPA axis activity (28, 29), the
LPS-induced up-regulation of preproN⁄OFQ synthesis is consistent
with engagement of endogenous hypothalamic N⁄OFQ in HPA axis
control. N⁄OFQ precursor mRNA is densely expressed in several
medial hypothalamic subregions implicated in stress responses,
including parvocellular paraventricular, arcuate, dorsal–medial and
supramammillary nuclei (2). Further work is required to identify
which preproN⁄OFQ-expressing neuronal sub-populations are acti-
vated after systemic LPS injection. Very few studies have addressed
the effect of stress on regulation of forebrain preproN⁄OFQ expres-
sion; however it is interesting to note that food deprivation in rats,
a probable stressor, does not alter hypothalamic expression of
N⁄OFQ precursor mRNA across various discrete subregions (e.g.
PVN, arcuate or ventromedial nuclei) (46).
The data obtained in the present study concerning the regulation
of NOP mRNA synthesis after LPS are entirely novel and are of
interest in the context of stress-induced changes in the central
N⁄OFQ-NOP system in vivo. NOP receptor mRNA is widely distrib-
uted throughout the central nervous system, but is particularly
densely expressed in hypothalamus and basal forebrain (3); there-
fore, an LPS-induced decrease in NOP mRNA level in the basal fore-
brain is of potential signiﬁcance, although we cannot rule out the
possibility that mRNA degradation may have inﬂuenced the NOP
ﬁndings. In the present study, the basal forebrain region encom-
passed a number of structures, including the caudate putamen, glo-
bus pallidus and BNST, which express variable NOP mRNA density.
Within the basal ganglia, the caudate putamen contains little NOP
mRNA-expressing neurones compared to the globus pallidus, which
is characterised by moderate density of NOP mRNA transcripts. By
contrast, the BNST is notably rich in NOP mRNA, being especially
high throughout the medial and posterolateral compartments (3).
Taken together, this suggests that the moderate reduction in NOP
mRNA after LPS could involve changes within the BNST. This
hypothesis would be consistent with observations of LPS-induced
neuronal activation of the PVN and dorsal BNST (47), in addition to
LPS activation of BNST and PVN afferents (48). Efferent projections
from hypothalamic nuclei such as PVN project to the BNST; there-
fore, it is also possible that the release of hypothalamic N⁄OFQ fol-
lowing LPS may correlate with the down-regulation of NOP
receptors in forebrain projection sites, including the BNST.
Enhanced forward drive of the HPA axis after activation of
immune-responsive brainstem neuronal populations and associated
activation of N⁄OFQergic neurones may underpin compensatory
changes in preproN⁄OFQ mRNA transcription. LPS may directly acti-
vate preproN⁄OFQ mRNA-expressing neurones because recent evi-
dence reveals that LPS via binding to Toll-like receptor 4 (TLR4)
complex directly activates DRG neurones (19). Furthermore, blocking
TLR4 action with targeted antibodies prevents the LPS-induction of
preproN⁄OFQ mRNA expression in DRG neurones, suggesting that
highly homologous systems exist in peripheral neurones and
immune cells for LPS binding and signal transduction. Whether
such mechanisms occur in central neurones is not known; however,
this would represent an entirely novel mechanism for direct LPS
activation of N⁄OFQergic neurones.
Conclusions
Administration of LPS is known to increase circulating pro-inﬂam-
matory IL-1b, IL-6 and TNFa, which drive a cascade of responses
including HPA axis activation (39, 49, 50). IL-1b strongly upregulates
N⁄OFQ secretion by immune cells (14), raising the possibility that
pro-inﬂammatory cytokines drive up-regulation in preproN⁄
OFQ mRNA in the hypothalamus. Although blockade of central NOP
receptors was shown to be effective in attenuating an acute mecha-
nism involved in the release of plasma ACTH observed up to 30 min,
endogenous N⁄OFQ appears to have little involvement in the sus-
tained hormonal response to LPS. The short-lasting inhibitory effect
of UFP-101 on plasma hormone release may therefore be reﬂective
of the truncated bioavailability of peptidic antagonists in vivo. The
results obtained in the present study reinforce the importance of
the endogenous N⁄OFQ-NOP system in the coordination of neuro-
endocrine and neuroimmune responses in inﬂammatory models.
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